ADC Therapeutics SA (ADCT) Fair Value 2026

ADCT · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-27, ADC Therapeutics SA (ADCT) trades at $1.12. QOC: 6.5/10. Value Trap Risk: 35/100 (LOW). 1/13 models active.

Key Facts

Ticker
ADCT
Price
$1.12
Quality Score
6.5/10
Value Trap Risk
35/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +51.1% upside with 31% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give ADCT?

1 Intrinsic Value Models vs. Current Price ($1.12)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $1.69 +51.1%

All Models Active

All 1 models are displayed above.

What Is ADC Therapeutics SA (ADCT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ADC Therapeutics SA is potentially undervalued at its current price of $1.12. Based on our 13-model framework, ADC Therapeutics SA's intrinsic value is estimated at a median fair value of $1.69 — representing +51.1% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About ADCT?

1 of 13 models are currently active for ADCT. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does ADCT Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, ADCT ranks #39 by Quality of Company score. CirclFi's QOC score of 6.5/10 evaluates 32 fundamental signals. A score of 6.5 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

ADC Therapeutics SA's positioning within the Drug Manufacturers - Specialty & Generic segment means that revenue per drug plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is ADCT a Value Trap?

CirclFi's Value Trap algorithm assigns ADCT a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for ADC Therapeutics SA. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, ADC Therapeutics SA earns a quality score of 6.5/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ADCT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ADCT's 1 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ADC Therapeutics SA Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

AKBAAkebia Therapeutics, Inc.QOC 6.6ACBAurora Cannabis Inc.QOC 6.5TEVATeva Pharmaceutical Industries LimitedQOC 6.7SNOASonoma Pharmaceuticals, Inc.QOC 6.3ANIKAnika Therapeutics, Inc.QOC 6.8ALVOAlvotechQOC 6.3RMTIRockwell Medical, Inc.QOC 5.8CBIHCannabis Bioscience International Holdings, Inc.QOC 4.3ALKSAlkermes plcQOC 8.6UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: AKBA · ACB · TEVA · SNOA · ANIK · ALVO · RMTI · CBIH · ALKS · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to ADCT?

7 companies across all industries closest to ADCT’s Quality of Company score of 6.5/10.

EDNEmpresa Distribuidora y Comercializadora Norte Sociedad AnónimaQOC 6.5ASNDAscendis Pharma A/SQOC 6.5UHALU-Haul Holding CompanyQOC 6.5ZIPZipRecruiter, Inc.QOC 6.5UISUnisys CorporationQOC 6.5APDAir Products and Chemicals, Inc.QOC 6.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: EDN · ASND · UHAL · ZIP · UIS · APD · NVDA

Where Does ADCT Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

ADCT is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About ADC Therapeutics SA’s Valuation?

What is ADC Therapeutics SA's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for ADC Therapeutics SA (ADCT). The Quality of Company score is 6.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ADCT overvalued or undervalued right now?

At $1.12, 1 of 1 active models suggest ADCT may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits ADC Therapeutics SA's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.5 mean for ADCT?

ADC Therapeutics SA's QOC of 6.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ADCT?

CirclFi analyzes ADCT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ADCT a value trap in 2026?

ADC Therapeutics SA's Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns ADC Therapeutics SA (ADCT) a Quality of Company score of 6.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/ADCT/ · Methodology
Primary sources for this ADCT valuation
  • Financial statements: ADC Therapeutics SA 10-K and 10-Q filings on SEC EDGAR (CIK 0001771910) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ADCT as of ; valuations recomputed .